Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1904 1
1910 1
1927 1
1935 1
1951 1
1956 1
1957 1
1963 1
1964 2
1965 1
1967 1
1968 2
1969 5
1970 7
1971 6
1972 2
1973 5
1974 2
1975 10
1976 6
1977 2
1978 3
1979 3
1980 3
1981 6
1982 4
1983 11
1984 12
1985 6
1986 10
1987 9
1988 17
1989 17
1990 24
1991 28
1992 17
1993 36
1994 31
1995 26
1996 34
1997 39
1998 42
1999 52
2000 70
2001 88
2002 87
2003 93
2004 115
2005 99
2006 122
2007 121
2008 153
2009 163
2010 168
2011 175
2012 209
2013 234
2014 326
2015 368
2016 378
2017 452
2018 456
2019 539
2020 634
2021 714
2022 741
2023 741
2024 310

Text availability

Article attribute

Article type

Publication date

Search Results

7,074 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacological Treatment of Tremor in Parkinson's Disease Revisited.
Pirker W, Katzenschlager R, Hallett M, Poewe W. Pirker W, et al. J Parkinsons Dis. 2023;13(2):127-144. doi: 10.3233/JPD-225060. J Parkinsons Dis. 2023. PMID: 36847017 Free PMC article. Review.
The pathophysiology of Parkinson's disease (PD) tremor remains incompletely understood and there is a lack of clinical trials specifically addressing its pharmacological treatment. ...The present review highlights the clinical essentials of parkinsonian …
The pathophysiology of Parkinson's disease (PD) tremor remains incompletely understood and there is a lack of clinical …
Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes.
Bae YJ, Kim JM, Sohn CH, Choi JH, Choi BS, Song YS, Nam Y, Cho SJ, Jeon B, Kim JH. Bae YJ, et al. Radiology. 2021 Aug;300(2):260-278. doi: 10.1148/radiol.2021203341. Epub 2021 Jun 8. Radiology. 2021. PMID: 34100679 Review.
Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. ...This review will improve understanding of recent advancements in nigral imaging of Parkinson disease. Published under a CC BY 4.0 license....
Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the midbrain. ...This review will impr …
Parkinson Disease.
Singer C, Reich SG. Singer C, et al. Clin Geriatr Med. 2020 Feb;36(1):xiii-xiv. doi: 10.1016/j.cger.2019.10.001. Epub 2019 Oct 5. Clin Geriatr Med. 2020. PMID: 31733706 No abstract available.
Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson's disease.
Kamath T, Abdulraouf A, Burris SJ, Langlieb J, Gazestani V, Nadaf NM, Balderrama K, Vanderburg C, Macosko EZ. Kamath T, et al. Nat Neurosci. 2022 May;25(5):588-595. doi: 10.1038/s41593-022-01061-1. Epub 2022 May 5. Nat Neurosci. 2022. PMID: 35513515 Free PMC article.
The loss of dopamine (DA) neurons within the substantia nigra pars compacta (SNpc) is a defining pathological hallmark of Parkinson's disease (PD). Nevertheless, the molecular features associated with DA neuron vulnerability have not yet been fully identified …
The loss of dopamine (DA) neurons within the substantia nigra pars compacta (SNpc) is a defining pathological hallmark of Parkinson' …
Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations.
Bloem BR, Marinus J, Almeida Q, Dibble L, Nieuwboer A, Post B, Ruzicka E, Goetz C, Stebbins G, Martinez-Martin P, Schrag A; Movement Disorders Society Rating Scales Committee. Bloem BR, et al. Mov Disord. 2016 Sep;31(9):1342-55. doi: 10.1002/mds.26572. Epub 2016 Mar 4. Mov Disord. 2016. PMID: 26945525 Review.
BACKGROUND: Disorders of posture, gait, and balance in Parkinson's disease (PD) are common and debilitating. ...We therefore recommend the development of such a PD-specific, easily administered, comprehensive gait and balance scale that separately asse …
BACKGROUND: Disorders of posture, gait, and balance in Parkinson's disease (PD) are common and debilitating. ... …
Effects of motor-cognitive training on dual-task performance in people with Parkinson's disease: a systematic review and meta-analysis.
Johansson H, Folkerts AK, Hammarström I, Kalbe E, Leavy B. Johansson H, et al. J Neurol. 2023 Jun;270(6):2890-2907. doi: 10.1007/s00415-023-11610-8. Epub 2023 Feb 23. J Neurol. 2023. PMID: 36820916 Free PMC article. Review.
Motor-cognitive training in Parkinson's disease (PD) can positively affect gait and balance, but whether motor-cognitive (dual-task) performance improves is unknown. ...Systematic searches were conducted in five databases and 11 studies with a total of 597 pe …
Motor-cognitive training in Parkinson's disease (PD) can positively affect gait and balance, but whether motor-cognitiv …
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson's disease.
Ding XB, Wang XX, Xia DH, Liu H, Tian HY, Fu Y, Chen YK, Qin C, Wang JQ, Xiang Z, Zhang ZX, Cao QC, Wang W, Li JY, Wu E, Tang BS, Ma MM, Teng JF, Wang XJ. Ding XB, et al. Nat Med. 2021 Mar;27(3):411-418. doi: 10.1038/s41591-020-01198-1. Epub 2021 Jan 18. Nat Med. 2021. PMID: 33462448
Animal studies implicate meningeal lymphatic dysfunction in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (PD). However, there is no direct evidence in humans to support this role(1-5). In this study …
Animal studies implicate meningeal lymphatic dysfunction in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease …
Rhythmic auditory stimulation for reduction of falls in Parkinson's disease: a randomized controlled study.
Thaut MH, Rice RR, Braun Janzen T, Hurt-Thaut CP, McIntosh GC. Thaut MH, et al. Clin Rehabil. 2019 Jan;33(1):34-43. doi: 10.1177/0269215518788615. Epub 2018 Jul 23. Clin Rehabil. 2019. PMID: 30033755 Clinical Trial.
SUBJECTS: A total of 60 participants (aged 62-82 years) diagnosed with idiopathic Parkinson's disease (Hoehn and Yahr stages III or IV) with at least two falls in the past 12 months. ...CONCLUSION: RAS training significantly reduced the number of falls in …
SUBJECTS: A total of 60 participants (aged 62-82 years) diagnosed with idiopathic Parkinson's disease (Hoehn and Yahr s …
Prospective Long-term Follow-up of Focused Ultrasound Unilateral Subthalamotomy for Parkinson Disease.
Martínez-Fernández R, Natera-Villalba E, Máñez Miró JU, Rodriguez-Rojas R, Marta Del Álamo M, Pineda-Pardo JÁ, Ammann C, Obeso I, Mata-Marín D, Hernández-Fernández F, Gasca-Salas C, Matarazzo M, Alonso-Frech F, Obeso JA. Martínez-Fernández R, et al. Neurology. 2023 Mar 28;100(13):e1395-e1405. doi: 10.1212/WNL.0000000000206771. Epub 2023 Jan 11. Neurology. 2023. PMID: 36631272 Free PMC article. Clinical Trial.
The primary outcome was the difference from baseline to 36 months after FUS-STN in the score of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor part (III) for the treated hemibody in the off-medication state. ...CLASSI …
The primary outcome was the difference from baseline to 36 months after FUS-STN in the score of the Movement Disorder Society-Unified Par …
Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.
Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A. Postuma RB, et al. Brain. 2019 Mar 1;142(3):744-759. doi: 10.1093/brain/awz030. Brain. 2019. PMID: 30789229 Free PMC article. Clinical Trial.
Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. ...Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis …
Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodi …
7,074 results